

SINGAPORE PAINCARE HOLDINGS LIMITED

Company Registration No.:201843233N
(Incorporated in the Republic of Singapore)

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE CATALIST RULES

The Board of Directors (“**Board**”) of Singapore Paincare Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) wishes to announce the following transactions that occurred during the six-month financial period from 1 July 2021 to 31 December 2021, pursuant to Rule 706A of the SGX-ST Listing Manual Section B: Rules of Catalist:

A. INCORPORATION OF A WHOLLY-OWNED SUBSIDIARY, SINGAPORE PAINCARE TCM WELLNESS PTE. LTD.

The Company had on 1 November 2021 incorporated a wholly-owned subsidiary in Singapore known as Singapore Paincare TCM Wellness Pte. Ltd. (“**SPTCMW**”). SPTCMW has a total issued and paid-up capital of S\$100.00 comprising 100 ordinary shares at S\$1.00 each.

The principal activities of SPTCMW will be the provision of clinic and other general medical services (Non-Western).

The incorporation of SPTCMW was funded through internal resources of the Group and is not expected to have any material impact on the consolidated net tangible assets and earnings per share of the Group for the current financial year ending 30 June 2022.

None of the Directors or the substantial shareholders or their respective associates has any interest, direct or indirect, in the incorporation of SPTCMW (other than through their respective shareholding interests in the Company, if any).

B. INCORPORATION OF A WHOLLY-OWNED SUBSIDIARY, DR+ MEDICAL SERVICES PTE. LTD.

The Company had on 9 December 2021 incorporated a wholly-owned subsidiary in Singapore known as Dr+ Medical Services Pte. Ltd. (“**Dr+**”). Dr+ has a total issued and paid-up capital of S\$100.00 comprising 100 ordinary shares at S\$1.00 each.

The principal activities of Dr+ will be the provision of clinic and other general medical services (Western).

The incorporation of Dr+ was funded through internal resources of the Group and is not expected to have any material impact on the consolidated net tangible assets and earnings per share of the Group for the current financial year ending 30 June 2022.

None of the Directors or the substantial shareholders or their respective associates has any interest, direct or indirect, in the incorporation of Dr+ (other than through their respective shareholding interests in the Company, if any).

By Order of the Board
Lee Mun Kam Bernard
Executive Director and Chief Executive Officer
14 February 2022

Singapore Paincare Holdings Limited (the “**Company**”) was listed on Catalist of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) on 30 July 2020. The initial public offering of the Company was sponsored by Novus Corporate Finance Pte. Ltd. (the “**Sponsor**”).

This announcement has been prepared by the Company and reviewed by the Sponsor, in compliance with Rule 226(2)(b) of the SGX-ST Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.